0000950172-24-000190.txt : 20240415 0000950172-24-000190.hdr.sgml : 20240415 20240415173025 ACCESSION NUMBER: 0000950172-24-000190 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240412 FILED AS OF DATE: 20240415 DATE AS OF CHANGE: 20240415 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hooks Corwin Dale CENTRAL INDEX KEY: 0001665347 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38898 FILM NUMBER: 24845620 MAIL ADDRESS: STREET 1: C/O CLOVIS ONCOLOGY, INC. STREET 2: 5500 FLATIRON PARKWAY CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Applied Therapeutics, Inc. CENTRAL INDEX KEY: 0001697532 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 545 FIFTH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-220-9226 MAIL ADDRESS: STREET 1: 545 FIFTH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: Applied Therapeutics Inc. DATE OF NAME CHANGE: 20170208 4 1 form4.xml X0508 4 2024-04-12 0001697532 Applied Therapeutics, Inc. APLT 0001665347 Hooks Corwin Dale C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400 NEW YORK NY 10017 true Chief Commercial Officer false Common Stock 2024-04-12 4 A 0 300000 0 A 300000 D Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One fourth (1/4th) of the compensatory Restricted Stock Units shall vest on April 12, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Restricted Stock Units shall vest each month thereafter, subject to the reporting person continuing to provide services through each such date. /s/ Shoshana Shendelman, as attorney-in-fact 2024-04-15